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Human immunodeficiency virus (HIV) infection was considered a contraindication for solid organ transplantation
(SOT) in the past. However, HIV management has improved since highly active antiretroviral therapy (HAART)
became available in 1996, and the long-term survival of patients living with HIV has led many transplant programs
to reevaluate their policies regarding the exclusion of patients with HIV infection.
Based on the available data in the medical literature and the cumulative experience of transplantation in HIV-
positive patients at our hospital, the aim of the present article is to outline the criteria for transplantation in HIV-
positive patients as recommended by the Immunocompromised Host Committee of the Hospital das Clı´nicas of the
University of Sa˜o Paulo.
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’ INTRODUCTION
Human immunodeficiency virus (HIV) infection was
considered a contraindication for solid organ transplantation
(SOT) in the past. Initial studies of patients who underwent
SOT reported worse outcomes in HIV-positive individuals
compared to HIV-negative individuals. A particular concern
was that posttransplant drug-induced immunosuppres-
sion could enhance the immunosuppressive state already
induced by HIV thus increasing morbidity, mortality and
organ waste (1).
The prognosis of HIV infection has improved dramatically
since highly active antiretroviral therapy (HAART) became
available in 1996. The impact of HAART has been supported
by the significant decrease in morbidity and mortality, with
a 10-year survival rate exceeding 90% (2). Consequently, the
long-term survival of HIV-infected patients as well as chronic
comorbidities other than opportunistic infection have increa-
sed. Some of these diseases, such as chronic kidney disease,
coronary artery disease, diabetes mellitus and liver failure,
have become important contributors of the poor prognosis
for these patients. Despite adequate control of viral replica-
tion with antiretroviral drugs (3,4), these comorbidities can
lead to end-stage organ failure with no alternative medical
treatment except transplantation.
Improvements in HIV management and the long-term
prognosis of patients living with HIV have led many
transplant programs to reevaluate their policies regardingDOI: 10.6061/clinics/2019/e941
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the exclusion of patients with HIV infection. The cumulative
evidence of transplantation in HIV-positive patients in the
era of HAART has shown that immunosuppressive therapy
did not negatively impact the posttransplant course of HIV
infection (5).
Most of the reported HIV-infected patients who under-
went SOT had to fulfill strict inclusion criteria relating to a
stable immunological and virological status. These patients
did not experience HIV replication after transplantation but
presented a transient decrease in CD4+ T-lymphocyte counts
during the first months posttransplant, but these counts
rapidly returned to baseline values. The other inclusion
criteria not related to HIV status were identical in HIV-
positive and HIV-negative patients (6).
Increased knowledge on appropriate HAART regimens for
SOT recipients has also contributed to the reported improved
outcomes. Integrase strand transfer- and nucleoside reverse
transcriptase inhibitor-based antiretroviral therapies have
been associated with better outcomes than protease inhibitor-
based therapies due to fewer drug interactions (6,7). These
two classes of antiretroviral drugs are not substrates of
CYP450; therefore, they are preferred and can be safely used
during the posttransplant period. If the pretransplantation
antiretroviral regimen is changed, it is important to wait at
least 6 months before transplantation.
Reported experiences of transplantation in the setting of
HIV infection are based mostly on kidney and liver trans-
plantation, with much less reported experience with the
transplantation of other solid organs. Nevertheless, significant
challenges have been raised when considering HIV-positive
candidates for SOT, including the impact of coinfection of HIV
with hepatitis C virus (HCV), hepatitis B virus (HBV) or other
viruses on the risk of opportunistic infection and malignancy
rates after transplantation, as well as the direct effect of HIV
itself and the potential of drug toxicities and interactions.
Based on the available data in the medical literature and
the cumulative experience of transplantation in HIV-positive
patients at our hospital, the aim of the present article is
to outline the criteria for transplantation in HIV-positive
patients as recommended by the Immunocompromised Host
Committee of the Hospital das Clínicas of the University of
São Paulo.
Kidney Transplant
HIV-positive patients are at increased risk for end-stage
renal disease (ESRD), and kidney transplantation has been
an effective and safe treatment in this scenario. Renal disease
in this population is related to multiple causes, including
HIV-associated nephropathy (HIVAN), acute renal injury,
renal toxicity of antiretroviral drugs and comorbid condi-
tions such as HCV, hypertension and diabetes (8). HIV
infection and diabetes increase the risk of ESRD, particularly
among black individuals. In populations without HIV or
diabetes, Choi et al. (9) reported a 4- to 5-fold increase in
the risk of ESRD in black individuals compared to white
individuals.
Several publications from the pre-HAART era corrobo-
rated the poor results among HIV-infected individuals who
underwent kidney transplantation, with a higher mortality
related to acquired immune deficiency syndrome (AIDS)
during the posttransplant period (ranging from 33% to 80%)
compared to the overall mortality among those maintained
in renal replacement therapy (1).
Experiences regarding kidney transplantation in HIV-
infected individuals in the era of HAART have changed
dramatically. Recent studies reported that the appropriate
selection of HIV-positive candidates for kidney transplant
has contributed to similar graft and patient survival rates in
HIV-positive and HIV-negative patients.
To date, the largest published study prospectively eval-
uated 150 HIV-infected individuals who underwent kidney
transplantation and were followed for up to five years at
19 transplant centers in the United States. The participants
were carefully selected using criteria of a CD4+ T-cell count
at least 200 cells/mm3 and an undetectable HIV viral load.
The one- and three-year patient survival rates were 94.6%
and 88.2%, respectively, and the graft survival rates were
90.4% and 73.7%, respectively. The graft survival rates were
similar to those reported for kidney transplant recipients
aged X65 years in the Scientific Registry of Transplantation
Recipients (SRTR) database. However, there were higher
rates of acute rejection at 1 and 3 years posttransplantation
(31% and 41%, respectively) (10).
A number of additional studies have demonstrated that
HIV-positive patients have patient and graft survival rates
similar to those of HIV-negative patients undergoing renal
transplantation in the HAART era (11-16), while some authors
have also reported elevated acute rejection rates ranging from
15% (17) to 44% (18).
A large retrospective review of the United Network for
Organ Sharing (UNOS) database from 2004 to 2006 compar-
ing 100 HIV-positive and 36,492 HIV-negative kidney trans-
plant recipients showed no differences in patient survival
rates (95.4% vs 96.2% p=0.32). However, the death-censored
graft survival rate was significantly lower in HIV-positive
patients (87.9% vs 94.9%, p=0.03). The donor’s age and
history of hypertension, a cold ischemia time of at least
16 hours and delayed graft function were associated with a
greater than fourfold increase in allograft loss among HIV-
positive patients (19). These findings suggest that marginal
kidney allografts are more prone to nephrotoxicity, which is
a particularly greater threat in HIV-positive individuals.
Two recent studies have evaluated the effect of HIV-HCV
coinfection on the outcomes of kidney transplant recipients.
The authors found that HIV-HCV coinfected patients had
inferior graft and patient survival rates compared to those
of HIV- or HCV-monoinfected individuals (20,21). In one
of these studies, the authors reported 10-year outcomes of
kidney transplant recipients from 2002 to 2012 using the
SRTR database. Monoinfected HIV-positive recipients had
similar 5- and 10-year graft survival rates when compared to
matched HIV- and HCV-negative controls. In addition,
compared to HIV-HCV coinfected patients, both HIV- and
HCV-monoinfected matched controls presented higher patient
survival rates at 5 and 10 years after transplantation. HCV
coinfection, panel reactive antibodies 480%, acute rejection
episodes and cold ischemia time410 hours were independent
risk factors for graft loss (20).
The largest Brazilian report of kidney transplantation in
53 HIV-infected recipients and 106 HIV-negative controls was
published by Vicari et al. (22). In this multicenter study, the
HIV-positive group presented a higher incidence of delayed
graft function (p=0.044), acute rejection (p=0.036) and median
number of infections per patient (p=0.018) compared to the
control group. The HIV-infected patient group presented
lower rates of 1-year patient survival (90.6% vs 100%,
po0.001) and graft survival (90.4% vs 98.1%, p=0.004) than
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the non-HIV-infected control group, but those numbers
were considered acceptable by the authors. In all centers,
the HIV-positive patients accepted for transplantation were
clinically stable on HAART with CD4+ cell counts above
200 cells/mm3 and undetectable HIV viral loads.
There is limited reported experience with simultaneous
kidney-pancreas transplantation in HIV patients (23-25), and,
only recently, the first case of pancreas transplant alone was
reported (26). However, the evidence has been sufficient to
support the feasibility of pancreas transplantation (either alone
or in association with kidney) for people living with HIV.
Liver Transplant
Liver disease is currently an important cause of non-AIDS-
related death in HIV-positive individuals (3) and is associated
with several factors, including hepatitis virus coinfection,
antiretroviral-related liver toxicity, alcohol abuse, nonalcoholic
cirrhosis, and hepatocellular carcinoma (HCC). Chronic HCV
and HBV coinfection is common in HIV-infected patients, with
estimated HIV-HCV coinfection rates of approximately 33%,
but rates can reach up to 70% in patients progressing to
cirrhosis (27,28).
Several studies have shown that HIV-infected patients
present higher mortality rates after their first liver disease
decompensation, and the absolute value of the Model For
End-Stage Liver Disease (MELD) score was associated with
significantly poorer survival rates in comparison with the
scores of HIV-negative patients (29-31). Murillas et al. (32)
showed that the mortality rate for a given MELD score in
HIV-infected patients was similar to the mortality rate in
non-HIV-infected patients with a MELD score that was
approximately 10 points higher. In addition, some studies
suggest that HIV-infected patients present a more aggressive
course of HCC than non-HIV-infected patients (33,34). This
scenario has contributed to the fact that few HIV-positive
patients are accepted for liver transplantation. Moreover,
those who are accepted have a reduced probability of suc-
cessfully undergoing transplantation due to poor clinical
conditions (27).
Initial studies performed before the advent of HAART
showed poor results (35,36). A French study demonstrated a
7-year survival rate of 36% among 11 HIV-infected liver
transplant recipients compared to almost 70% among non-
HIV-infected liver transplant recipients during the same
period (37). Even in the post-HAART era, a cohort study
with the UNOS database evaluating the outcomes of liver
transplantation in HIV-positive individuals who underwent
transplantation between 1997 and 2006 showed inferior
overall survival rates among HIV-positive patients (n=138)
compared to those of HIV-negative patients (n=30520). Survi-
val rates at 2 and 3 years posttransplantion were 70% and
60% in HIV-positive recipients compared to 81% and 77%,
respectively, in the controls (po0.05) (38).
Liver transplantation outcomes in HIV-HCV coinfection
patients have been associated with higher mortality rates.
HCV recurrence represented the major challenge in HIV-
HCV coinfected patients in the past (15). Two important
prospective studies, one in Spain (39) and the other in the
United States (40), performed with HIV-HCV coinfected
patients undergoing liver transplantation showed similar
results. HIV-HCV coinfected patients had lower patient
and graft survival rates and more acute cellular rejection
than did monoinfected HCV recipients in both studies.
Nevertheless, the use of the newer directly acting antiviral
(DAA) agents for HCV treatment, resulting in a sustained
viral response (SVR), has changed this scenario dramati-
cally. Data have shown that the use of new DAA agents in
HIV-HCV coinfected patients following liver transplanta-
tion is associated with improved SVR rates (41,42). More-
over, both pretransplant and early posttransplant treatment
have changed this scenario (43,44).
In contrast, patients with liver disease associated with
chronic HBV and nonviral etiologies undergoing liver trans-
plantation have presented excellent results with a reported
overall survival rate of 100% at 5 years (28). Although the
reported experience in liver transplantation for HCC in HIV-
positive patients is limited, the comparison of the results of
liver transplantation for HCC has shown similar results
between HIV-positive and HIV-negative recipients regarding
HCC recurrence, disease-free survival time and overall sur-
vival rates (45,46).
Heart Transplant
Cardiovascular disease is a significant cause of morbid-
ity in patients living with HIV, and heart transplantation
has become an acceptable therapeutic modality in selected
HIV-positive patients. The 2016 International Society for
Transplantation listing criteria for heart transplantation has
considered including HIV-positive candidates in special
circumstances. Centers performing heart transplantation
in this population should have structured protocols with
multidisciplinary teams, adequate access to pharmacologic
expertise, therapeutic drug monitoring for immunosup-
pressants, and laboratory access to antiviral drug resis-
tance testing as needed (47).
However, the current experience is limited to a few repor-
ted cases and small series. Some of these reported cases
occurred in patients who underwent heart transplantation at
the time when antibody-based HIV testing was not routinely
available (48,49). In the pre-HAART era, Castel et al. (50)
published a case report of a 39-year-old HIV-positive male
patient in Spain with a high CD4 count and undetectable
HIV viral load receiving an antiretroviral regimen based on
three analog reverse transcriptase inhibitors (zidovudine,
lamivudine and abacavir) and who underwent heart trans-
plantation. The patient had one episode of rejection without
infectious episodes and was alive 3 years posttransplant.
Additional case reports in the post-HAART era have been
documented; the majority of these patients underwent heart
transplantation with a high CD4+ T-cell count and unde-
tectable HIV viral load and presented satisfactory outcomes
without AIDS-related complications after transplantation (51).
In one case report, a 39-year-old patient was diagnosed
with HIV infection nine years before heart transplanta-
tion. He had a history of opportunistic diseases, including
Pneumocystis jirovecii pneumonia at the time of HIV diagnosis
and disseminated Kaposi sarcoma diagnosed a few months
afterwards. In the posttransplantation follow-up period of 30
months, this patient experienced occasional decreases in the
CD4+ T-cell count to less than 100 cells/mm3, but he did not
present any opportunistic disease. The main complications
after transplantation were recurrent episodes of rejection (52).
The largest case series was reported by the Columbia
Presbyterian Medical Center with 5 HIV-positive patients who
underwent heart transplantation. All patients had a CD4+
T-cell count above 400 cells/mm3 and an undetectable HIV
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viral load; all patients were alive with a mean follow-up
of 30 months, none of whom presented significant AIDS-
related infections or complications after the transplant pro-
cedures (53).
Lung Transplant
The first case of a successful lung transplant in an HIV-
infected patient with cystic fibrosis was described in 2009
(54). More recently, three additional cases of lung transplant
in HIV-infected patients were reported. Although one patient
developed recurrent and refractory acute rejection leading
to bronchiolitis obliterans syndrome, the other two only
experienced mild acute rejection with good quality of life and
good lung function after transplantation (55).
At the end of 2014, the International Society of Heart and
Lung Transplantation considered the possibility of including
HIV-positive individuals on the waiting list for lung trans-
plantation (56). The document, however, recommends that
the lung transplantation procedure in HIV-positive patients
should be limited to centers with expertise in the care of
these patients.
Reported experiences are still scarce and based on very
few cases. At the same time, the majority of lung transplant
centers consider listing HIV-positive lung transplant candi-
dates on a case-by-case basis.
Hematopoietic Stem Cell Transplantation
Despite improvement in the control of HIV infection after
the introduction of HAART, HIV-infected patients have a
considerably higher risk (15–24 times greater) of developing
hematological malignancies , including Hodgkin (HL) and
non-Hodgkin lymphoma (NHL), acute leukemia and myelo-
dysplastic syndromes, than non-HIV-infected patients (57).
Studies have shown similar prognoses among patients with
HIV-related and non-HIV-related lymphomas (57,58).
Hematopoietic stem cell transplantation (HSCT) has been
suggested as a treatment option for HIV-infected patients
with hematological diseases, but before the era of HARRT,
these procedures were mostly unsuccessful. After the intro-
duction of HAART, several transplantation centers have
published their experience with autologous HSCT in patients
with HIV-related lymphoma (HRL) with some success.
A retrospective study of the European Group for Blood and
Marrow Transplantation Lymphoma Working Party found
no difference in the outcome of HIV-infected and noninfected
patients with HL and NHL who underwent autologous
HSCT (59).
A case-control study including HIV-positive and HIV-
negative patients with NHL observed similar long-term out-
comes between cases and controls. The nonrelapse mortality
and the 2-year disease-free survival were similar between the
HIV-positive group and HIV-negative group (11% versus 4%,
p=0.18, and 75% versus 56%, p=0.33, respectively) (60).
A recent clinical trial involving 40 transplants in patients
with HRL and 151 controls showed that the outcome dif-
ferences between HIV-infected patients and controls were
not statistically significant. Among HRL patients, the 1-year
and 2-year overall survival rates were 87% and 82%, respec-
tively. In this trial, 20% of the patients had a detectable viral
load at the time of transplantation, and the mean pretrans-
plant CD4+ T-cell count was 249 cells/mm3 (range 39–
797 cells/mm3) (61).
Autologous HSCT, where indicated, is the treatment of
choice for patients with HRL. It is important to ensure that
there are still therapeutic options for HIV treatment before
indicating HSCT for these patients. Most studies have shown
that there is temporary HIV replication with an increased
viral load and decreased CD4+ T-cell count shortly after
the transplant procedure, but this period is rarely asso-
ciated with HIV-related complications such as opportunis-
tic infections. Patients with a detectable viral load or low
CD4+ T-cell count should not be excluded from the HSCT
procedure (60).
Data supporting the performance of allogeneic HSCT in
HIV-infected patients are more limited than for autologous
HSCT. Most of the current data are based on retrospective
studies of a single institution including a small number
of patients. The report of a case series from 1983 to 2010
observed significant improvement in the survival rates of
HIV-infected patients undergoing allogeneic HSCT using
HAART compared to those of patients without HAART
(62). In a case series including five patients with hemato-
logic malignancies who underwent allogeneic HSCT, the
patients received tenofovir/emtricitabine in combination
with either efavirenz (one patient) or raltegravir (four
patients). There were no major complications, no need to
switch HAART an no increased transplant-related mortal-
ity, and the patients maintained an undetectable HIV viral
load (63).
One multicenter clinical trial included 17 HIV-infected
patients with different hematologic disorders (acute myeloid
leukemia, acute lymphocytic leukemia, myelodysplastic
syndrome, and HRL) who underwent allogeneic HSCT.
The 100-day related mortality was 0%, the graft-versus-host
disease (GVHD) incidence was 41%, and the 1-year overall
rate was 57% (64).
A large inpatient data set in the United States for HSCT
from 1998 to 2012 showed no differences in inpatient
mortality, healthcare-acquired infections and GVHD rates
between HIV-positive (n=108 patients) and HIV-negative
patients, and the study concluded that HSCT can be safely
performed in HIV-positive patients (65). In allogeneic HSCT,
however, HIV-positive patients had a significantly higher
incidence of nontuberculous mycobacteria and cytomega-
lovirus infection than HIV-negative patients.
Therefore, as with autologous HSCT, allogeneic HSCT
should also be considered as a standard therapeutic option
for HIV-infected patients who meet the usual eligibility
criteria for this procedure. It is suggested, however, to
exclude patients with opportunistic infections who do not
have therapeutic options for HIV treatment at the time of
transplantation. Drug interaction may further hamper the
management of these patients in the immediate posttrans-
plantation period.
Several studies performing allogeneic HSCT in HIV-
positive patients (based on the ‘‘Berlin Patient’’) have been
conducted with the intention of changing the natural history
of HIV. The ‘‘Berlin Patient’’ underwent transplantation for
treatment of acute myeloid leukemia with a donor with the
delta32 mutation, which corresponds to the deletion of the
CCR5 receptor from the cells. After 8 years of transplanta-
tion, the patient continues to have an undetectable HIV viral
load in serum and in other tissues. However, another five
patients who were transplanted with donors with the CCR5
deletion died (57,66,67).
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Pediatric Transplantation
Although the reported experience with transplantation
in the HIV-positive pediatric population is limited to small
case series reports, the concerns and challenges are similar to
those in the adult population.
The main experience with SOT in HIV-positive children
was published in 1990. Authors from the University of
Pittsburgh reported 10 HIV-infected children among 25 SOT
recipients in the pre-HAART period between 1981 and 1988.
Five patients underwent transplantation after HIV infection
(3 liver, 1 kidney, and 1 heart) (35). The median age of the
children was 15 years (ranging from 6 months to 16 years),
and 2 of them died posttransplantation. One died 3.5 years
later from a systemic CMV infection attributed to AIDS, and
the other died 9 months later from a preexisting central ner-
vous system disorder that was not specified by the authors.
More recently, there was a report of a liver transplantation
for a 9-year-old child with HIV who developed acute liver
failure associated with efavirenz-based HAART; the patient
was effectively treated with a combination of lamivudine,
zidovudine and raltegravir (68).
Another group reported a successful case of kidney
transplantation in an 8-year-old patient who developed
nephropathy related to HIV infection that was treated with
lamivudine, abacavir and lopinavir/ritonavir. The authors,
however, highlighted the importance of carefully monitoring
the blood tacrolimus level because of the drug interaction
between the calcineurin inhibitors and protease inhibitors (69).
There is slightly more literature on HSCT than on SOT for
HIV-positive children, although the majority of the pediatric
HSCT cases have been reported together with adults who
underwent autologous (70,71) or allogeneic transplantation
(62,72).
There is a case report of successful high-dose chemother-
apy, including rituximab, followed by autologous HSCT in a
13-year-old child with congenital HIV and refractory Burkitt
lymphoma (73). At the time of hematopoietic transplanta-
tion, the patient was on his third antiretroviral regimen with
lopinavir/ritonavir, lamivudine, tenofovir and stavudine,
based on HIV genotypic drug resistance findings. Due to a
temporary interruption of HAART during high-dose che-
motherapy, there was a transient drop of the CD4+ count
to 12 cells/mm3 and an increased viral load up to 585,000
copies/ml. After restarting antiretroviral treatment, the
patient
́
s CD4+ count increased, and the viral load became
undetectable. This patient remained in complete remission
for a 26-month period.
Most of the reported cases have outlined uneventful
posttransplantation evolution with no AIDS-related compli-
cations (60,62,70-73). Nevertheless, in contrast to the avail-
able data in adults, HSCT as part of a salvage strategy after
high-dose chemo/radiotherapy in HIV-related NHL has not
yet been established for children.
Acceptability criteria for transplantation.
Current position for transplantation in HIV-positive can-
didates at the Hospital das Clínicas of the University of
São Paulo:
Kidney Transplant
Accept HIV-positive candidates: yes.
Specific criteria to accept the following:
 CD4+ T-lymphocyte countX200 cells/mm3 during at least
6 months before transplantation
J Children:o1 year: CD4+ T-cell countX750 cells/mm3
or CD4+ T-cell percentage of total lymphocytesX26%;
1–5 years: CD4+ T-cell count X500 cells/mm3 or
CD4+ T-cell percentage of total lymphocytesX22%;X6
years: the same criteria used for adults and adolescents.
 Undetectable HIV viral load in plasma using ultrasensitive
techniques (o50 copies/mL) during at least 6 months
before transplantation
 Use of the same HAART scheme during at least 6 months
before transplantation
 Absence of active opportunistic infection and malignancy
 Absence of chronic wasting or severe malnutrition
 No evidence of advanced fibrosis or cirrhosis in patients
with a history of HBV or HCV
 Appropriate follow-up with providers experienced in the
management of HIV
Specific criteria to reject:
 Patients with a previous history of the following oppor-
tunistic diseases under risk of further reactivation during
the posttransplantation period in the absence of available
target prophylaxis: progressive multifocal leukoencephalo-
pathy, chronic intestinal cryptosporidiosis, primary central
nervous system lymphoma, and visceral Kaposi’s sarcoma
 Patients with a previous history of antiretroviral resistance
and no currently available antiretroviral drug options based
on antiretroviral sensitivity testing can be considered a
potential contraindication.
Liver Transplant
Accept HIV-positive candidates: yes.
Specific criteria to accept the following:
 CD4+ T-lymphocyte count X100 cells/mm3 during at
least 6 months before transplantation
J If the patient presents intolerance to HAART due to
severe terminal liver disease, transplant should be
considered even with CD4+ T-cell p100 cells/mm3
and detectable viral load once there is a perspective of
HIV control and immune reconstitution after reintro-
duction of HAART in the posttransplantation period.
J Children: o6 years: CD4+ T-cell percentage of total
lymphocytes X15%; X6 years: the same criteria as
used for adults and adolescents.
 Undetectable HIV viral load in plasma using ultrasensi-
tive techniques (o50 copies/mL) during at least 6 months
before transplantation
 Use of the same HAART scheme during at least 6 months
before transplantation
 Absence of active opportunistic infection and malignancy
 Absence of chronic wasting or severe malnutrition
 Appropriate follow-up with providers experienced in the
management of HIV
Specific criteria to reject:
 Patients with a previous history of the following oppor-
tunistic diseases at risk of further reactivation during the
5
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posttransplantation period in the absence of available
target prophylaxis: progressive multifocal leukoencephalo-
pathy, chronic intestinal cryptosporidiosis, primary central
nervous system lymphoma, and visceral Kaposi’s sarcoma
 Patients with a previous history of antiretroviral resistance
and no currently available antiretroviral drug options
based on antiretroviral sensitivity testing can be consid-
ered a potential contraindication.
Heart Transplant
Accept HIV-positive candidates: yes.
Specific criteria to accept the following:
 CD4+ T-lymphocyte count X200 cells/mm3 during at
least 3 months before transplantation
J Children: o1 year: CD4+ T-cell count X750 cells/
mm3 or CD4+ T-cell percentage of total lymphocytes
X26%; 1–5 years: CD4+ T-cell count X500 cells/mm3
or CD4+ T-cell percentage of total lymphocytes
X22%; X6 years: the same criteria as used for adults
and adolescents.
 Undetectable HIV viral load in plasma using ultrasensitive
techniques (o50 copies/mL) during at least 3 months
before transplantation
 Use of the same HAART scheme during at least 6 months
before transplantation
 Absence of active opportunistic infection and malignancy
 Absence of chronic wasting or severe malnutrition
 No evidence of advanced fibrosis or cirrhosis in patients
with a history of HBV or HCV
 Appropriate follow-up with providers experienced in the
management of HIV
Lung Transplant
Accept HIV-positive candidates: consider on a case-by-
case basis.
There are limited data in the literature about the safety of
lung transplantation in HIV patients. Despite the recent
worldwide acceptance of HIV-positive patients for lung
transplantation, the Lung Transplant Group of our hospital
decided to individually evaluate HIV-positive candidates
before listing for transplantation.
Hematopoietic Stem Cell Transplant
Accept HIV-positive candidates: yes
Specific criteria to accept the following:
 CD4+ T-lymphocyte countX250 cells/mm3 during at least
6 months before transplantation
J Children:o1 year: CD4+ T-cell countX750 cells/mm3
or CD4+ T-cell percentage of total lymphocytesX26%;
1–5 years: CD4+ T-cell count X500 cells/mm3 or
CD4+ T-cell percentage of total lymphocytes X22%;
X6 years: the same criteria as used for adults and
adolescents.
 Undetectable HIV viral load in plasma using ultrasensitive
techniques (o50 copies/mL) during at least 6 months
before transplantation
J Consider patients with a detectable HIV viral load to
transplant in special situations
 Use of the same HAART scheme during at least 6 months
before transplantation
 Absence of active opportunistic infection and malignancy
Pediatric Transplant
Accept HIV-positive candidates: yes
Specific criteria to accept the following:
 Because there are insufficient data in the pediatric
population, the recommendations should be according to
the adult’s guidelines. However, we need to consider the
absolute number of CD4+ T-cells in children based on
their age (Table 1).
Final consideration
Solid organ transplantation in HIV-positive patients has
become an acceptable and safe procedure, with graft and
patient survival rates equivalent to those of HIV-negative
patients. The current acceptability criteria for transplantation
developed for the Hospital das Clínicas of the University of
Sao Paulo were based on the available reported data at the
moment. These recommendations will be reviewed and may
change based on new data that reinforce or refute the current
evidence.
Transplantation for organs from HIV-infected donors to
HIV-infected recipients is not allowed in Brazil, and this
topic was not included in this manuscript. More data
regarding the effectiveness and safety of this approach
must be demonstrated to guide us in how we proceed with
this issue.
Table 1 - HIV infection stage based on age-specific CD4+ T-lymphocyte count or CD4+ T-lymphocyte percentage of total lymphocytes
in children o13 years of age.
Age on date of CD4+ T-lymphocyte test
o1 year 1–5 years X6 years
Stage Cells/mm3 % Cells/mm3 % Cells/mm3 %
1 41,500 434 X1,000 X30 X500 426
2 750-1,499 26-33 500-999 22-29 200-499 14-25
3 o750 o26 o500 o22 o200 o14
Adapted from: Centers for Disease Control and Prevention (CDC). Revised surveillance cases definition for HIV infection – United States, 2014. MMWR
2014;63(No. RR-3):1-10 (74)
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